Profil bibliographique

Jonathan S. Berek

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

474Publications signalées

32442Citations signalées

3Affiliations récentes

Institutions déclarées

Stanford Health Care Stanford Medicine Stanford University

Domaines associés

Ovarian cancer diagnosis and treatmentEndometrial and Cervical Cancer TreatmentsCervical Cancer and HPV ResearchPARP inhibition in cancer therapyIntraperitoneal and Appendiceal Malignancies

Publications récentes

Accès ouvert 2026 preprintOpenAlex

Risk-Stratified versus Cytology-Based Triage of Non-HPV 16/18-Positive for Detection of High-Grade Cervical Intraepithelial Neoplasia: Protocol of a Non- Inferiority Randomized Controlled Trial

Kehinde S. Okunade, Omolola Salako, Adaiah SOIBI-HARRY, Iyabo Y. Ademuyiwa et autres

0 citationsResearch Square

2026 articleOpenAlex

What burdens patients with endometrial cancer most: results of the international EXPRESSION XI/IMPROVE survey with 2.761 patients

Jalid Sehouli, Lukas Chinczewski, Olena Sukhina, Tibor A. Zwimpfer et autres

0 citationsInternational Journal of Gynecological Cancer

2026 articleOpenAlex

Open label, multicenter, phase 2 study of farletuzumab ecteribulin, a folate receptor alpha-targeting antibody-drug conjugate, alone and in combination with lenvatinib in platinum-resistant ovarian cancer

Robert M. Wenham, Sharad Ghamande, Ana Oaknin, Jonathan S. Berek et autres

0 citationsInternational Journal of Gynecological Cancer

2026 articleOpenAlex

What burdens patients with endometrial cancer most: results of the international EXPRESSION XI/IMPROVE survey with 2.761 patients

Jalid Sehouli, Lukas Chinczewski, Olena Sukhina, Tibor A. Zwimpfer et autres

0 citationsInternational Journal of Gynecological Cancer

Accès ouvert 2025 articleOpenAlex

Randomized Controlled Trial of Impact of Mobile Health Technologies on Human Papillomavirus Vaccination Uptake in Mothers of Vaccine-Eligible Girls in Lagos, Nigeria (mHealth-HPVac)

Kehinde S. Okunade, Ayomide I. Fayinto, Temitope V. Adekanye, Matthew Allsop et autres

1 citationJCO Global Oncology

Accès ouvert 2025 articleOpenAlex

Cancer of the ovary, fallopian tube, and peritoneum: 2025 update

Malte Renz, Michael Friedländer, Jonathan S. Berek

37 citationsInternational Journal of Gynecology & Obstetrics

2025 articleOpenAlex

1131P Upgrading the performance of ECOG performance status in recurrent ovarian cancer (ECOG+)

Omali Pitiyarachchi, H-W. Sim, Ryan P. O’Connell, Anne Lanceley et autres

0 citationsAnnals of Oncology

Accès ouvert 2025 articleOpenAlex

FIGO Cancer Report 2025: Transforming gynecologic oncology through global equity, technological innovation, and preventive strategies

Sarikapan Wilailak, Jonathan S. Berek

3 citationsInternational Journal of Gynecology & Obstetrics

Accès ouvert 2025 articleOpenAlex

Cancer and fertility management: FIGO best practice advice

Nikhil Purandare, Francisco Ruiloba, Long Nguyen‐Hoang, Sarikapan Wilailak et autres

6 citationsInternational Journal of Gynecology & Obstetrics

Accès ouvert 2025 preprintOpenAlex

Topical 5-Fluorouracil and Imiquimod for the Treatment of High-Grade Cervical Intraepithelial Neoplasia: Protocol for a Randomised Open-Label Controlled Trial (TOPFIT-CIN Study)

Kehinde S. Okunade, Ayomide I. Fayinto, Iyabo Y. Ademuyiwa, Babatunde Akodu et autres

0 citationsResearch Square

Accès ouvert 2025 reviewOpenAlex

Cancer in pregnancy: FIGO Best practice advice and narrative review

Surabhi Nanda, Melanie Nana, Long Nguyen‐Hoang, Sumaiya Adam et autres

12 citationsInternational Journal of Gynecology & Obstetrics

2025 conference-abstractOpenAlex

Outcomes for patients with platinum-sensitive recurrent ovarian cancer treated with prolonged PARP inhibitor therapy.

Corrine A. Nief, Jonathan S. Berek, Talayeh Ghezelayagh

0 citationsJournal of Clinical Oncology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.